Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKI

NCT01602952 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

85

Enrollment

INDUSTRY

Sponsor class

Conditions

Leukemia
Leukemia, Myeloid
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Philadelphia Chromosome
Hematologic Diseases

Interventions

DRUG: Radotinib

Sponsor

Il-Yang Pharm. Co., Ltd.